Autopsy report · NCT00698685

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

“Pentostatin/alemtuzumab regimen had greater risk of graft failure.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 5 months after it had already started.
• Ran for about 5 years 3 months before it stopped.
• 14 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Arizona

Sponsor type

University, hospital or other

Conditions

Leukemia; Lymphoma; Hodgkin's Disease; Hematologic Neoplasms; Multiple Myeloma; Carcinoma, Renal Cell

Interventions

Pentostatin; Alemtuzumab; Allogeneic hematopoietic stem cell transplantation

Participants

14

Sites

2

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.